Status: Recruiting
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).
Participants needed: 131
Trial details
Phase: Phase 2, Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Sir Mortimer B. Davis - Jewish General HospitalUpdated: Jun 30, 2026Locations: 4
Eligibility criteria
Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic/... [+12]
Patients with previous pelvic radiation [+4]